Experienced in Diffuse Midline Glioma H3 K27M-Mutant

Dr. Behnam B. Badie

Neurosurgery
City Of Hope Medical Foundation
1500 E Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
City Of Hope Medical Foundation
1500 E Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Behnam Badie is a Neurosurgery provider in Duarte, California. Dr. Badie is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, Awake Craniotomy, and Gastrostomy.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010
CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma
A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Other, Biological
Study Drugs: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Biological
Study Drug: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes
Study Phase: Phase 1
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Biological, Procedure
Study Drugs: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Study Phase: Phase 1
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2025
Intervention Type: Biological, Other, Procedure
Study Drug: HER2(EQ)BB?/CD19t+ T cells
Study Phase: Phase 1
View 3 Less Clinical Trials

67 Total Publications

Towards a Steerable Neurosurgical Robot for Debulking of Brain Mass Lesions.
Towards a Steerable Neurosurgical Robot for Debulking of Brain Mass Lesions.
Journal: IEEE robotics and automation letters
Published: July 21, 2025
Similar Doctors
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. William G. Loudon
Neurosurgery | General Surgery
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. William G. Loudon
Neurosurgery | General Surgery
101 East Valencia Mesa Drive, 
Fullerton, CA 
 (16.4 miles away)
714-734-3280
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Loudon is a General Surgeon and a Neurosurgery provider in Fullerton, California. Dr. Loudon is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Bulging Fontanelles, Primitive Neuroectodermal Tumor (PNET), Hydrocephalus, and Sunken Fontanelles. Dr. Loudon is currently accepting new patients.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Ramin J. Javahery
Neurosurgery
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Ramin J. Javahery
Neurosurgery

Coast Neurosurgical Associates A Medical Group

2888 Long Beach Blvd, Suite 240, 
Long Beach, CA 
 (25.3 miles away)
562-595-7696
Languages Spoken:
English
See accepted insurances

Ramin Javahery is a Neurosurgery provider in Long Beach, California. Dr. Javahery is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Cerebral Arteriovenous Malformation, Subarachnoid Hemorrhage, Apoplexy, Thrombectomy, and Gastrostomy.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Gabriel Zada
Neurosurgery
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Gabriel Zada
Neurosurgery

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (13.8 miles away)
323-442-8444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gabriel Zada is a Neurosurgery provider in Los Angeles, California. Dr. Zada is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Pituitary Tumor, Hypothalamic Tumor, Brain Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Gamma Knife Radiosurgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Badie's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 11 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile